Nearly half of women age 45 years or older who experience symptoms of overactive bladder report their current treatment does not address their OAB symptoms, according to a recent survey conducted by The Harris Poll on behalf of Allergan.
The Food and Drug Administration has granted tentative approval for Basaglar (insulin glargine injection), which is used to improve glycemic control in adults with Type 2 diabetes and in combination with mealtime insulin in adults and pediatric patients with Type 1 diabetes.
NBTY on Tuesday named Steven Cahillane CEO. A 25-year consumer goods industry veteran, Cahillane comes to NBTY from Coca-Cola, where he led the successful integration of Coca‐Cola Enterprises' North American bottling operation and drove significant market share gains as president of Coca-Cola Americas.
Advertising claims for weight loss supplement products feed the Federal Trade Commission with the highest settlement costs within the dietary supplement and functional food category, according to a new web-based, members-only tool from the Council for Responsible Nutrition.